Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Feb 22;19(7):pyw018. doi: 10.1093/ijnp/pyw018

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2016. Published by Oxford University Press on behalf of CINP.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 1. — Patient disposition. ^aPaliperidone palmitate 3-month formulation (PP3M) doses: 175, 263, 350, or 525mg eq., ie, 273, 410, 546, or 819mg. ^bPaliperidone palmitate 1-month formulation (PP1M) doses: 50, 75, 100, or 150mg eq. (78, 117, 156, or 234mg. ^c21 patients were excluded from the efficacy analyses due to a manufacturing issue with a small lot of PP3M. ^dAll patients were to receive the first PP1M injection of 150mg eq. (234mg) on day 1 and the second injection of 100mg eq. (156mg) on day 8, both in the deltoid muscle.